The $330M Bet to Dethrone Roche's Eye Drug Empire

But Ollin thinks they've found the champ's weakness.

Same Targets, Sharper Weapons

OLN324 and Vabysmo go after the same two proteins, but the engineering under the hood is very different. Think of it like two restaurants serving the same cuisine: one uses sharper knives, fresher ingredients, and a better oven.

Two key differences stand out. First, OLN324 delivers a higher molar dose (more drug molecules per injection). Second, it's a smaller protein, which Ollin believes lets it penetrate deeper into retinal tissue. In eye disease, getting the drug where it needs to go is half the battle.

The combination of these features could mean faster results, more complete fluid removal, and potentially longer gaps between injections. At least, that's the theory. But Ollin has early data to back it up.

The Head-to-Head That Turned Heads

Ollin ran something unusual for a young biotech: a randomized, head-to-head Phase 1b trial (called JADE) directly comparing OLN324 against Vabysmo in over 150 patients. Most startups avoid head-to-head comparisons this early. Ollin went looking for a fight.

The results, reported in early 2026, were striking. In DME patients, OLN324 showed about 75% greater fluid reduction at Week 1 and roughly 50% greater reduction at Week 12 compared to Vabysmo. By Week 12, nearly 90% of OLN324 patients were edema-free, versus 57% on Vabysmo. That's a big gap for a disease where clearing fluid from the retina is the whole ballgame.

In wet AMD, the story was more nuanced. Anatomic outcomes were similar between the two drugs, but OLN324 showed numerically better vision gains. On safety, OLN324 had zero cases of intraocular inflammation, while Vabysmo had one. Small numbers, but clean enough to keep moving forward.

Armed with those results, Ollin completed an end-of-Phase 2 meeting with the FDA and received scientific advice from the European Medicines Agency. Both regulatory interactions apparently went well, because the company is now planning to launch global Phase 3 trials in the second half of 2026. That's exactly where the $330 million comes in.

Why This Market Is Worth Fighting For

The global AMD treatment market alone is projected to hit roughly $11.5 billion in 2026. Add in DME and other retinal conditions, and you're looking at a therapeutic area approaching $20 billion. The patient populations are enormous and growing, driven by aging demographics and the global diabetes epidemic.

But the real opportunity isn't just market size; it's unmet need. Current anti-VEGF treatments work, but they demand punishing commitment from patients. Monthly or bimonthly injections into the eye, regular monitoring visits, and the constant fear of missing an appointment and losing ground. Real-world adherence consistently falls short of clinical trial protocols, which means real-world outcomes are worse than the data suggests.

Every company in this space is chasing the same holy grail: fewer injections with better results. Vabysmo made progress by extending some patients to dosing every 16 weeks. If OLN324 can demonstrate even longer durability in Phase 3, the clinical and commercial implications would be massive.

A Crowded Ring, Getting More Crowded

Ollin isn't the only challenger circling Vabysmo. The retinal disease landscape is buzzing with competition. Long-acting tyrosine kinase inhibitors from EyePoint (EYP-1901) and others promise injections just once or twice a year. Gene therapies from REGENXBIO/AbbVie and 4D Molecular Therapeutics aim to eliminate repeat dosing entirely with one-time treatments. Meanwhile, a wave of aflibercept biosimilars is poised to reshape the pricing floor for older anti-VEGF drugs.

But Ollin occupies a specific strategic lane. They're not trying to reinvent the delivery mechanism or pioneer gene therapy. They're taking the proven bispecific antibody approach that made Vabysmo a blockbuster and arguing they can simply do it better. It's the biotech equivalent of building a faster version of a car people already love to drive.

The $330 Million Question

Phase 3 trials in ophthalmology are expensive, global, and take years. Ollin will need to enroll thousands of patients across multiple countries and prove that the JADE results hold up at scale. The FDA and EMA will want to see not just better retinal drying, but durable vision gains and a clean safety profile over extended follow-up.

The good news: the regulatory path is well-worn. Dozens of anti-VEGF drugs have navigated it before. The endpoints are clear, the comparators are established, and the patient populations are large enough to recruit efficiently.

The risk? Phase 1b data doesn't always survive the jump to Phase 3. Larger trials have a way of humbling promising early results. And Roche won't sit still; they have the resources, the relationships, and the installed base to defend Vabysmo aggressively.

Still, $330 million from some of the smartest investors in healthcare is a powerful vote of confidence. Ollin has head-to-head data, regulatory alignment, and now the cash to prove their case. For millions of patients stuck on the injection treadmill, a better option can't come soon enough.